Search - tctmd.com

Displaying 1 - 20 of 65

Sort: Relevancy | Date

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

News Conference News AHA 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

November 08, 2025

Frail Older Patients With AF May Fare Better Switching to DOAC

News Daily News

Frail Older Patients With AF May Fare Better Switching to DOAC

August 05, 2025

Biomarker-Based Risk Score Better Predicts Stroke in AF Than Clinical Tools

News Daily News

Biomarker-Based Risk Score Better Predicts Stroke in AF Than Clinical Tools

March 19, 2025

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

News Daily News

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

February 14, 2025

Top Heart Rhythm News of 2024

News Daily News

Top Heart Rhythm News of 2024

December 27, 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presentation ESC 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presenter: Gi-Byoung Nam

September 01, 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

September 01, 2024

Lower-Dose Edoxaban May Be an Option After Age 80: ENGAGE AF-TIMI 48 Analysis

News Daily News

Lower-Dose Edoxaban May Be an Option After Age 80: ENGAGE AF-TIMI 48 Analysis

July 12, 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

News Conference News NY Valves 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

June 06, 2024

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

News Daily News

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

February 02, 2024

Top Heart Rhythm News of 2023

News Daily News

Top Heart Rhythm News of 2023

December 26, 2023

Efficacy and safety of anticoagulation with edoxaban in patients with Atrial high rate-episodes (AHRE) durations ≥ 24 hours - The NOAH-AFNET 6 trial -

Presentation AHA 2023

Efficacy and safety of anticoagulation with edoxaban in patients with Atrial high rate-episodes (AHRE) durations ≥ 24 hours - The NOAH-AFNET 6 trial

Presenter: Nina Becher

November 14, 2023

FRAIL-AF: Warfarin Beats NOACs in Frail Elderly With AF

News Conference News ESC 2023

FRAIL-AF: Warfarin Beats NOACs in Frail Elderly With AF

August 28, 2023

NOAH-AFNET 6: Edoxaban for Atrial High-Rate Episodes: No Help, Some Harm

News Conference News ESC 2023

NOAH-AFNET 6: Edoxaban for Atrial High-Rate Episodes: No Help, Some Harm

August 25, 2023

Andexanet Alfa, Reversal Agent for Factor Xa Inhibitors, Boosts Hemostasis

News Daily News

Andexanet Alfa, Reversal Agent for Factor Xa Inhibitors, Boosts Hemostasis

June 05, 2023

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

News Daily News

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

November 23, 2022

Apixaban Again Linked to Less Bleeding in AF Patients

News Daily News

Apixaban Again Linked to Less Bleeding in AF Patients

Michael O'Riordan

October 31, 2022

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

What’s Going to Be Hot at ESC 2022?

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

August 22, 2022

Fewer Diabetic Complications Seen When NOACs Given for AF

News Daily News

Fewer Diabetic Complications Seen When NOACs Given for AF

February 22, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.